Similar to PD-1 and Tim-3, additional HLA-independent checkpoints including CD96, CD112R, and TIGIT are increased in expression on NK cells in cancer patients and have been reported to restrain NK cell killing ability in vitro and in vivo. Here, PDCD1 is linked to cancer.